SCHEMBL7675615

SCHEMBL7675615

O=C(Nc1c(Cl)cncc1Cl)C(O)c1c(Cc2ccc(F)cc2)[nH]c2ccc(O)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 10/20 0.46
PDE4B Q07343 10/20 0.46
PDE4C Q08493 10/20 0.46
PDE4D Q08499 10/20 0.46
ALOX5 P09917 4/20 0.40
P2RX7 Q99572 1/20 0.40
PTGES O14684 1/20 0.35
GPER1 Q99527 1/20 0.33
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
GABRA4 P48169 1/20 0.32
UBE2N P61088 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4960029 0.81 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DALOX5
SCHEMBL2052164 0.73 PDE4A (0.68) PDE4APDE4BPDE4CPDE4DP2RX7
SCHEMBL6760292 0.69 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DALOX5
SCHEMBL5533925 0.67 MAPT (0.46) PDE4APDE4BPDE4CPDE4DALOX5
SCHEMBL5636904 0.67 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DALOX5
Awd-12-281 SCHEMBL155120 0.63 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DP2RX7
SCHEMBL2052162 0.63 PDE4A (0.70) PDE4APDE4BPDE4CPDE4DP2RX7
Awd-12-281 SCHEMBL29413256 0.63 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DP2RX7
Awd-12-281 SCHEMBL5638136 0.62 PDE4A (0.98) PDE4APDE4BPDE4CPDE4D
Awd-12-281 SCHEMBL5638122 0.62 PDE4A (0.98) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020119971-A1 Antiinflammatory agents; skin disorders; central nervous system disorders ELBION AG (DE) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119971-A1 Antiinflammatory agents; skin disorders; central nervous system disorders PDE4A, TPH1, PDE12 PDE4A 1/4885PDE4B 4/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.